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ABSTRACT
Advances in the last decade have established the osteocyte, the most abundant cell in bone, as a dynamic and multifunctional
cell capable of controlling bone homeostasis by regulating the function of both osteoblasts and osteoclasts. In addition,
accumulating evidence demonstrates that osteocyte function is altered in several skeletal disorders, and targeting osteocytes
and their derived factors improves skeletal health. Despite the remarkable progress in our understanding of osteocyte biology,
there has been a paucity of information regarding the role of osteocytes in the progression of cancer in bone. Exciting, recent
discoveries suggest that tumor cells communicate with osteocytes to generate a microenvironment that supports the growth
and survival of cancer cells and stimulates bone destruction. This review features these novel findings and discussions regarding
the impact of chemotherapy on osteocyte function and the potential of targeting osteocytes for the treatment of cancer in
bone. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral
Research.
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Introduction
The skeleton is a multifunctional tissue that provides supportand protection to various organs of the body, regulates
mineral homeostasis and hematopoiesis, enables body move-
ment, andhasmultiple endocrine functions in thebody. Bonesare
composed of a calcified extracellular matrix and a multitude of
cells that establish complex interactions to maintain bone
homeostasis. Osteoclasts derive from hematopoietic precursors
and are responsible for bone resorption, a process that breaks
down bone into its mineral and collagenous constituents. Cells of
the osteoblastic lineage derive from mesenchymal stem cells, a
multipotent cell population with capacity to differentiate into
osteoblasts, osteocytes, adipocytes, chondrocytes, and myo-
blasts.(1,2) The main function of osteoblasts is bone formation.
Osteoblasts secrete a variety of proteins that constitute the bone
matrix and become mineralized. Upon completing bone forma-
tion, a fraction of osteoblasts becomes entombed bymineralized
matrix and differentiates into osteocytes. Osteocytes are themost
abundant cells in bone and considered permanent residents of
skeletal tissue, with an estimated half-life of 25 years;(3,4) however,
the life of many osteocytes may be shorter.(5,6) Although initially
described as passive cells, we now know that osteocytes are
multifunctional cells that sense and transduce mechanical forces
in bone, and coordinate both bone formation and bone
resorption by secreting cytokines that control the activity of
osteoblasts and osteoclasts (reviewed in Delgado-Calle and
Bellido(7) and Bonewald(8)).
As occurs in other organs in the body, turnover of cells and
matrix also takes place in bone and is essential tomaintain tissue
integrity. Through a complex and tightly regulated process
known as “bone remodeling,” old or damaged bone is removed
by osteoclasts and subsequently replaced by new bone formed
by osteoblasts.(9) Under physiological conditions, bone remod-
eling occurs in compartmentalized structures known as “bone
remodeling units,” which enable bone resorption and bone
formation to occur in a balanced and sequential manner at
the same anatomical location.(10–13) Alteration of osteoblasts
and osteoclasts activities within these remodeling units leads to
the development of bone disorders. Imbalance in favor of
resorption results in bone loss and a deterioration of bone
microarchitecture, whereas elevation of bone formation is
usually associated with increased bone mass.
Different kinds of cancer cells can grow in bone. Primary bone
tumors are rare and account for a small portion of newly
diagnosed cancers. These bone tumors arise from cells present
in the bone tissue and include osteosarcomas, which typically
occur in adolescents and are thought to arise from osteo-
blasts;(14) chondrosarcomas, which begin in cartilage and are
more frequent in adults; and Ewing sarcomas and chordomas.
Other cancers begin in bone but do not arise frombone cells. For
instance, multiple myeloma is a cancer of plasma cells that
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originates in the bone marrow and causes bone tumors and
bone lesions in 80% ofmyeloma patients.(15,16) Lastly, metastatic
bone tumors develop from cancer cells that originated in
another area of the body and then migrate and spread to the
bone. Bone metastases are more common than primary bone
cancers in adults. In themajority of patients, the primary tumor is
located in the prostate or the breast, which account for 70% of
skeletal metastases (reviewed in Macedo and colleagues(17)).
Bone metastases are frequently one of the first signs of
disseminated disease in cancer patients and typically indicate
a short-term prognosis. The growth of cancer cells in bone has a
deleterious impact on patients’ quality of life and represents a
significant cause of morbidity and mortality.(18–20) Patients with
bone tumors frequently present with severe pain, impaired
mobility, spinal cord compression, pathologic fractures, bone
marrow aplasia, and hypercalcemia.
Autopsy observations made in women with breast cancer led
Paget to propose the “seed and soil” hypothesis in which the
bone (soil) supports the growth of the breast cancer cells
(seed).(21) Later, work by Mundy(22) and by TJ Martin and
colleagues(23) showed that indeed cancer cells establish
interactions with osteoblasts and osteoclasts present in the
bone/bone marrow compartment leading to a “vicious cycle”
that alters bone homeostasis and fuels tumor growth (recently
reviewed in Croucher and colleagues(24)). The growth of cancer
cells in the bone/bone marrow microenvironment alters normal
bone remodeling, thus leading to the development of bone
disease. In cancer-induced osteolytic bone disease, as occurs
in breast cancer metastasis and multiple myeloma, tumor
cells stimulate osteoclastogenesis and bone resorption, primar-
ily in a parathyroid-related protein (PTHrP)/receptor activator of
nuclear factor kappa-B ligand (RANKL)-mediated manner.
Increased bone resorption releases bone matrix–embedded
growth factors such as transforming growth factor beta
(TGF-b),(25,26) which further stimulates tumor growth and
bone destruction.(27) Concomitantly, cancer cells secrete factors
(interleukin [IL]-7, IL-3, DickkopfWnt Signaling Pathway Inhibitor
1 [DKK-1], and Sclerostin) and promote epigenetic changes that
suppress osteoblast differentiation and function (reviewed in
Giuliani and colleagues,(28) MacDonald and Delgado-Calle,(29)
and Adamik and colleagues(30)). As a result, bone is resorbed at a
rate faster than it is formed, causing the development of overt
“osteolytic lesions,” which severely weakens the bone and
elevates fracture risk. In osteoblastic lesions, as occurs in
osteosarcomas and prostate cancer metastasis, tumor-derived
factors, including insulin-like growth factor (IGF)-1 and 2,
TGF-b, bone morphogenetic proteins (BMPs), platelet-derived
growth factor (PDGF), endothelin-1 (ET-1), and fibroblast growth
factors (FGFs) stimulate the differentiation and bone-forming
activity of osteoblasts (reviewed in Guise and Mundy(31)).
However, the bone produced is formed primarily of woven
tissue and exhibits compromised mechanical properties. In turn,
osteoblasts produce growth factors such as IL-6, monocyte
chemoattractant protein 1 (MCP-1), or vascular endothelial
growth factor (VEGF) that further stimulate tumor growth.(31)
More recent studies revealed that cancer cells also interact with
other cells in the bone/bone marrow microenvironment,
including osteocytes, adipocytes, endothelial cells, and immune
cells. In particular, growing evidence indicates that osteocytes
are important contributors to tumor progression in bone and
the associated skeletal disease.(29,32,33) This review summarizes
the current knowledge of the role of osteocytes in the
progression of cancer in bone, the mechanisms by which
osteocytes communicate with cancer cells, and the potential of
targeting osteocytes for the treatment of cancer-induced bone
disease.
Role of Osteocytes in Bone Physiology
Osteocytes live deep within mineralized bone in small pockets
known as lacunae. Osteocytes have long cytoplasmic processes
that run through small channels called canaliculi, establishing a
complex and extensive canalicular network in the mineralized
bone.(2,8) These processes reach periosteal and endocortical
surfaces of cortical bone, as well as the bone marrow surface.
Through this lacunar-canalicular system, osteocytes connect
among themselves, establish cell-to-cell interactions with cells
on the bone surfaces, and distribute autocrine/paracrine
secreted factors.
Work performed over the last decade has brought about a
revolution of our understanding of the role of osteocytes in
bone biology. Osteocytes regulate bone formation by
controlling osteoblast differentiation, survival, and function.
Earlier work showed that osteocytes are the main mechano-
sensors in the skeleton by sensing mechanical forces and
translating them into biochemical signals that promote bone
formation.(34,35) Supporting this notion, targeted deletion of
osteocytes impairs the bone anabolic response to mechanical
loading.(36) Some of the molecular cues by which osteocytes
regulate bone formation have been identified in more recent
studies. Extensive clinical and animal data demonstrated that
osteocytes negatively regulate osteoblast viability and func-
tion by secreting Wnt signaling antagonists, including DKK-1
and Sclerostin (reviewed in Delgado-Calle and Bellido,(7)
Delgado-Calle and colleagues,(37) and Baron and Kneissel(38)).
Both DKK-1 and Sclerostin inhibit Wnt signaling by blocking
the binding of Wnt ligands to Frizzled receptors and low-
density lipoprotein receptor-related proteins (LRP) 5 and
6.(39,40) Patients with mutations in DKK-1 and SOST, the gene
encoding Sclerostin, as well as mice with genetic deletion of
these genes, exhibit increased bone mass, mainly due to
elevated osteoblast number and bone formation. These initial
observations attracted considerable attention to DKK-1 and
Sclerostin and the role of the Wnt signaling pathway in bone.
Extensive work in this area showed that osteocytes coordinate
the osteogenic response to mechanical forces by down-
regulating Sclerostin, thus enabling activation of canonical
Wnt signaling.(37,39–42) Sclerostin is also downregulated by
parathyroid hormone (PTH), an FDA approved agent used in
the clinic to stimulate bone formation in osteoporotic
patients.(43–47) Several neutralizing antibodies against DKK-1,
Sclerostin, and other components of the Wnt signaling
pathway (i.e., LRP4) have been developed and have shown
promising therapeutic outcomes for patients with osteoporo-
sis and other skeletal diseases (discussed in the section
“osteocytes and their derived factors as targets for the
treatment of cancer that grows in bone”). However, the cell
orchestrating the anabolic actions of the Wnt signaling
pathway in bone has remained elusive. One hypothesis is
that osteocytes coordinate the anabolic actions of canonical
Wnt/b-catenin signaling activation in bone. Consistent with
this notion, genetic stimulation of Wnt/b-catenin signaling in
osteocytes results in increased osteoblast number and bone
formation, leading to net bone gain.(48) These results contrast
with those observed in mice expressing the same dominant
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active b-catenin transgene in osteoblasts, which also exhibit
bone gain, but mainly due to decreases in bone resorption.(49)
Osteocytes also produce a number of cytokines controlling
the differentiation and function of osteoclasts. The high bone
mass displayed by mice lacking RANKL in osteocytes supports
that osteocytes are a major source of RANKL during adult bone
remodeling bone.(50,51) Osteoprotegerin (OPG) expression,
which competes with RANKL for binding to receptor activator
of nuclear factor k (RANK) in osteoclast precursors, is regulated
by the Wnt/b-catenin pathway, and mice lacking b-catenin in
osteocytes have increased osteoclast number and bone
resorption.(52) Moreover, osteocytes are an additional source
of secreted macrophage colony-stimulating factor (M-CSF) in
bone.(53) An area of intense investigation is the role of apoptotic
osteocytes in the regulation of local bone resorption. It has been
shown that decreases in osteocyte life span accompany the
increased bone resorption and bone loss associated with
estrogen and androgen deficiency, glucocorticoid excess,
mechanical disuse, and aging.(54–56) Further, osteocyte apopto-
sis is spatially, temporally, and functionally linked to the removal
and replacement of damaged bone. Mechanistically, osteocyte
apoptosis increases the expression of RANKL in neighboring
osteocytes, which in turn recruits osteoclast precursors and
stimulates their differentiation.(57–59) Consistent with this
notion, pharmacologic inhibition of apoptosis impairs the
increase in RANKL expression induced by unloading or
overloading.(57,58) In contrast, inhibiting osteocyte apoptosis
with a bisphosphonate that targets osteocytes and osteoblasts
also prevented the increase in RANKL but did not prevent the
bone loss induced by unloading,(59) indicating that apoptotic
osteocytes can also regulate osteoclast precursor recruitment to
specific areas in a RANKL-independent manner (ie, OPG, high
mobility group box 1 [HMGB1], tumor necrosis factor [TNF], IL-6,
and VEGF).(60,61)
Role of Osteocytes in Tumor Metastasis to Bone
Metastasis of cancer cells to a secondary site is a multistep
process involving detachment from the primary tumor and
egress to the bloodstream.(24,62) Tumor cells circulate and leave
the bloodstream to finally colonize the bone, homing to specific
niches within the bonemarrow.(24,62) It is becoming evident that
cancer cell colonization and homing to bone is not a casual
event but rather regulated by the existence of “premetastatic”
niches that prime the arrival of metastatic cells to areas with
favorable conditions for cancer cell survival. However, the
specific mechanisms by which cancer cells localize and arrive to
these areas remain to be determined. Similarly, the role of
osteocytes in the early steps of tumor metastasis and homing to
bone is unclear. Genetic ablation of osteocytes, induced by
diphtheria toxin administration, increased the homing of
myeloma cells to particular areas of the bone and increased
total tumor burden.(63) Mechanistic studies showed that the
expression of IL-6, hepatocyte growth factor (HGF), hypoxia-
inducible factor (HIF)-1, cytokines known to be involved in
myeloma migration and homing to the bone marrow, as well as
immune-suppressive cell populations (myeloid-derived sup-
pressor cells, regulatory T and B cells), were elevated in the bone
marrow of mice with apoptotic osteocytes. In addition, it has
been shown that C-X-C motif chemokine ligand 12 (CXCL12)
signaling through the C-X-C chemokine receptor type 4 (CXCR4)
receptor in cancer cells plays an important role in the retention
and homing to bone of both cancers that develop in the bone
marrow, as well as metastatic cancer cells.(64–66) Osteocytes
produceCXCL12and therefore could activate theCXCL12-CXCR4
signaling axis in cancer cells, favoring their homing to bone.(67)
However, alternatively it is also possible that osteocytes prevent
the migration and arrival to bone of metastatic breast cancer
cells. In vitro studies show that mechanically stimulated
osteocytes reduced the transendothelial migration of breast
cancer cells.(68) Further, interactions between osteocytes and
endothelial cells decrease the expression of matrix metal-
loproteinase 9 (MMP-9), an enzyme known to facilitate the
movement of metastatic cancer cells through the extracellular
matrix.(68) The disparity between these findings suggest that
interactions between osteocytes and tumor cells are context and
cancer specific. In fact, osteocytes have distinct effects in the
migratory potential of breast and prostate cancer cells.(69)
Although osteocytes have the potential to participate in the
establishment of bone metastasis and homing to specific areas
of the bone, their role in this process remains largely unknown.
Future research efforts are required to determine the specific
contribution of osteocytes to the relocation and homing of
cancer cells to bone. Identification of the cellular and molecular
events that mediate the cross-talk between cancer cells and
bone cells should help to identify therapeutic targets that can
interfere with the first steps of bone metastasis.
Role of Osteocytes in Cancer Cell Dormancy and
Tumor Proliferation in Bone
Once cancer cells arrive to bone, most of them undergo
apoptosis with only a few becoming dormant and surviving.
Eventually, when better conditions for growth are established,
dormant cells are activated and proliferate, thus initiating the
bone destruction process.(24,70) Because dormant cells are
resistant to chemotherapies and can repopulate the tumor
after treatment cessation, it is critical to understand the
mechanisms controlling dormancy to either maintain dormant
cells or awaken them after reestablishing sensitivity to
chemotherapy. The specific mechanisms regulating tumor cell
dormancy and reactivation in bone are just starting to be
revealed. New data indicate that osteoblasts and osteoclasts are
important players in the regulation of dormancy. In vitro and in
vivo experiments have shown that upon arrival to bone, cancer
cells interact with osteoblasts on the endosteal surface, which in
turn maintains cancer cells in a dormant state by inhibiting
their proliferation.(24,71–73) In contrast, induction of osteoclast
differentiation and bone resorption decreases the number of
dormant cancer cells present in the endosteal niche, suggesting
that osteoclasts control the reactivation of dormant
cells.(24,71,74–76) As of today, there is no experimental data
linking osteocytes to the regulation of cancer cell dormancy.
However, given the critical role of osteocytes in bone
remodeling, it is possible that they regulate dormancy through
indirect actions on osteoblasts and osteoclasts. Future studies
are warranted to determine the role of osteocytes in cancer cell
dormancy.
After reactivation, cancer cells establish multiple interactions
with cells in the bone/bone marrow microenvironment that
favor a continued stimulation of tumor growth. As discussed
earlier, tumor cells initiate a “vicious cycle” in which cancer cells
produce and stimulate other cells to secrete factors that increase
osteoclast resorption. In turn, bone resorption releases growth
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factors from the bone matrix that promote tumor proliferation
and survival.(77,78) Although originally not included in this
“vicious cycle,” new findings support that osteocytes also
contribute to the generation of a microenvironment that is
conducive to tumor proliferation through both direct and
indirect mechanisms. Osteocytes are the main source of RANKL
in adult bone. In addition, the prevalence of osteocytes
expressing RANKL is increased in bones involved with myeloma
cells (see the section “osteocytes and their derived factors as
targets for the treatment of cancer that grows in bone”).(79)
Furthermore, myeloma cells increase the expression of IL-11 in
osteocytes, a cytokine that favors osteoclast differentiation.(80)
Thus, it is possible that by secreting pro-osteoclastogenic
cytokines and stimulating bone resorption, osteocytes contrib-
ute to the release of growth factors from the matrix fueling
tumor growth.
Osteocytes also regulate tumor proliferation by direct
interactions with cancer cells (Fig. 1). Osteocytes establish
physical interactions with myeloma cancer cells located in the
endocortical surface of the bone.(79) These physical interactions
result in the activation of Notch signaling in myeloma cells, a
pathway that mediates cell-to-cell communication between
neighboring cells and controls proliferation/death programs.(79)
Activation of Notch signaling by osteocytes increases cyclin D1
mRNA expression and accelerates the proliferation of myeloma
cells.(79) In vitro, pharmacological inhibition of Notch signaling
using gamma-secretase inhibitors (GSIs) fully prevents the
increase in myeloma proliferation induced by osteocytes.(79)
Because dysregulation of Notch signaling contributes to the
progression of several cancers in bone,(81,82) this pathway
provides a therapeutic opportunity to treat cancers in bone.
However, Notch signaling plays critical roles in several organs,
and systemic inhibition of Notch has several side effects that
limit its use in the clinic.(82,83) Thus, it is important to identify the
specific Notch components (receptors and ligands) involved in
the interactions between cancer cells and bone cells as this is key
for the development of safer therapies. In this regard, both
autocrine and paracrine (with osteoblasts) activation of Notch
receptor 1 and 2 signaling stimulate the proliferation of
myeloma cells.(84–87) Interestingly, osteocytes could use a
different set of Notch receptors to communicate with myeloma
cells, as bidirectional communication between osteocytes and
myeloma cells changed the Notch receptor repertoire in both
cell types, with a rapid and marked increase in the expression of
Notch receptor 3 and Notch receptor 4.(79)
Osteocytes also contribute to the growth of metastatic
cancers in bone. For instance, Keller and colleagues demon-
strated in vivo that the growth of prostate cancer cells in bone
increases intramedullary pressure.(88) Because osteocytes are the
main mechanotransducers in bone, they investigated whether
these changes in physical forces in bone alter osteocyte
function. In vitro, conditioned media from pressurized osteo-
cytes increased the proliferation, migration, and invasion
capacity of prostate cancer cells.(88) Mechanistic studies revealed
that these effects were partially mediated by the osteocyte-
derived C-C motif chemokine ligand 5 (CCL5) and matrix
metalloproteinases.(88)
In concert, these findings identify osteocytes as important
pro-tumorigenic cells. However, because most of the data
currently available are from in vitro and ex vivo co-culture
systems, future studies are required to assess the specific
contribution of osteocytes to tumor growth in vivo.
Osteocytes and Dysregulation of Bone
Remodeling in Bone Colonized by Cancer Cells
The growth of cancer cells in bone alters the function of
osteoblasts and osteoclasts, resulting in profound alterations of
bone remodeling that ultimately compromised bone integrity.
We now have confirmation that osteocytes actively participate
in the development of osteolytic lesions (Fig. 1). Experiments
performed in the frame of multiple myeloma have shown that
the bone remodeling compartment is disrupted by myeloma
cells,(89) allowingmyeloma cells to interact with other cells in the
bone marrow, including osteocytes. It is well accepted that
myeloma cells stimulate bone resorption through the produc-
tion of several pro-osteoclastogenic factors and via interactions
with osteoblasts (reviewed in Silbermann and Roodman(20)
and in Roodman(90,91)). However, in vitro and in vivo work
demonstrates that myeloma cells also increase the expression of
RANKL in osteocytes.(79) In addition, the expression of the Wnt
target geneOPG is decreased in osteocytes exposed tomyeloma
cells, thus increasing even further the RANKL/OPG ratio and the
Fig. 1. Communication between cancer cells and osteocytes contrib-
utes to tumor progression and bone destruction. Cell-to-cell communi-
cation between osteocytes and myeloma cells results in bidirectional
Notch signaling activation, leading to osteocyte apoptosis and
stimulation of myeloma cell proliferation. In addition, osteocyte
apoptosis leads to increased RANKL expression, which acts as a
chemoattractant to recruit osteoclast precursors to local areas and
promote their differentiation, thus initiating bone resorption. In
addition, myeloma cells increase SOST/Sclerostin production by
osteocytes, which in turn decreases Wnt signaling and inhibits
osteoblast differentiation and function. Recent findings support that
the beneficial effects of bisphosphonates and proteasome inhibitors in
cancer patients are also due to the prevention of osteocyte (and
osteoblast) apoptosis. In addition, preclinical data have shown that
targeting the osteocyte-derived factor Sclerostin stimulates osteoblast
differentiation and new bone formation in bones infiltrated with
cancer cells. Similarly, pharmacologic inhibition of RANKL, abundantly
expressed by osteocytes in adult bone, prevents skeletal-related events
in cancer patients.
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osteoclastogenic potential of osteocytes.(79) Myeloma cells also
increase the expression of other pro-osteoclastogenic cytokines
in osteocytes, such as interleukin (IL)-11.(80) In addition,myeloma
cells decrease the life span of osteocytes in bone, as occurs in
other bone disorders characterized by bone loss (see the section
“role of osteocytes in bone physiology”). Myeloma patients
exhibit more apoptotic osteocytes in bone than healthy subjects
or patients with monoclonal gammopathy of undetermined
significance (MGUS), a condition with abnormal paraprotein
serum levels but absence of the typical multiple myeloma
symptoms.(80) Similarly, in preclinical models of multiple
myeloma bone disease, osteocyte apoptosis is increased in
bone areas infiltratedwithmyeloma cells.(79) Mechanistic studies
demonstrated thatmyelomacells induceosteocyte apoptosis via
physical interactions with osteocytes. Cell-to-cell communica-
tion between myeloma cells and osteocytes activate Notch
signaling in osteocytes, triggering caspase-3 mediated apopto-
sis.(79) In addition, TNFa secreted by myeloma cells sustains/
amplifies osteocyte apoptosis.(79) Moreover, Giuliani and col-
leagues showed that myeloma cells also stimulate osteocyte
apoptosis by inducing autophagy.(92) Consistent with the notion
that apoptotic osteocytes attract osteoclast precursors to initiate
targeted local bone resorption, conditioned media from
osteocytes exposed tomyeloma cells stimulates the recruitment
of osteoclast precursors, and this effect was fully prevented by
an inhibitor of osteocyte apoptosis.(79) Together, these
results identify apoptotic osteocytes as important
contributors to the exaggerated bone resorption that drives
the development of cancer-induced osteolytic lesions.
In addition to increased osteoclast number, myeloma-
induced bone lesions also exhibit reduced osteoblasts and
decreased bone formation. Importantly, inhibition of osteoblast
differentiation and new bone formation persists even after
complete remission and therefore plays a critical role in the
pathogenesis of myeloma bone disease. Several mechanisms
involved in the suppression of osteoblasts by myeloma cells
have been identified over the years.(16,20,28,90) Much attention
has been drawn to the osteocyte-derived factor Sclerostin in the
recent years.(29) Circulating Sclerostin levels are increased in
postmenopausal women with endocrine responsive breast
cancer and in patients with prostate cancer, particularly in
individuals receiving androgen deprivation therapy.(93,94) High
levels of SOST/Sclerostin have also been detected in breast
cancer cells.(95) Similarly, elevated Sclerostin expression is found
in the circulation of myeloma patients compared with healthy
subjects or MGUS patients.(96,97) Indeed, high SOST mRNA
expression was found in plasma cells isolated from small cohorts
of patients with myeloma,(98,99) identifying myeloma/cancer
cells as a source of Sclerostin. However, in a study including
more than 630 myeloma patients, bone marrow plasma cell
SOST mRNA expression was not different compared with
healthy controls, nor was it detected in 56 human or murine
myeloma cells lines,(100) suggesting that the elevated serum
Sclerostin was driven by another source. Consistent with this
notion, the number of osteocytes expressing Sclerostin is higher
in bones injected with myeloma cells.(79,101) Moreover, in vitro
experiments show that myeloma cells increase SOST mRNA
expression in osteocytes, and conditioned media from osteo-
cytes co-cultured with myeloma cells decreased the expression
of Wnt target genes and osteoblast differentiation markers
in osteoblastic cells cultured under mineralizing conditions.(79)
As discussed below, genetic and pharmacologic inhibition of
Sclerostin increased osteoblast number and induced new bone
formation in preclinical models of multiple myeloma bone
disease.(97,100,101) DKK-1, another Wnt antagonist expressed by
osteocytes, is also elevated in the circulation of myeloma
patients and breast cancer patients.(102) In preclinical models,
anti-DKK-1 successfully prevented myeloma-induced bone
disease and had variable effects on tumor burden leading to
clinical trials.(102–104)
In osteosarcoma and prostate cancer metastasis, tumor cells
secrete factors that stimulate both bone resorption and bone
formation. In these cancers, osteoblastic lesions are formed
due to increased matrix production by osteoblasts. However,
the new bone being deposited is poorly organized, formed
primarily of woven tissue.(105,106) The specific role of the
osteocytes as either initiators or drivers of the osteoblastic
disease is unclear. Osteocytes, in addition to osteoblasts, may act
as a cell of origin for osteosarcoma.(107) High levels of the
osteocyte-derived factor Sclerostin are also found in prostate
cancer patients with osteoblastic bone metastasis.(108,109) Yet,
whether Sclerostin contributes to the osteoblastic disease in
these patients remains to be determined.
Osteocytes and Their Derived Factors as Targets
for the Treatment of Cancer That Grows in Bone
Chemotherapeutic agents used in the clinic for the treatment of
cancer in bone alter normal bone homeostasis by affecting both
osteoblast and osteoclast function. In this section, we will focus
on recent results showing that osteocyte function is also
affected by chemotherapy, and discuss new findings supporting
the potential of targeting osteocytes for the treatment of cancer-
induced bone disease (Fig. 1).
Antiresorptives
Bisphosphonates are considered the mainstay therapy for
cancer patients with bone disease. Bisphosphonates inhibit
the activity of osteoclasts and prevent bone loss induced by
cancer cells, thus reducing the risk of fracture. The beneficial
effects of bisphosphonates on the skeleton are also due to the
prevention of osteoblast and osteocyte apoptosis, an effect that
depends on the regulation of Connexin 43 (Cx43) signaling
between neighboring cells.(110) Conditioned media from
MLO-Y4 osteocyte cells treated with bisphosphonates reduced
the growth, migration, and invasion of MDA-MB-231 human
breast cancer cells.(111) These inhibitory effects appear to be
mediated by Cx43, as mice with impaired Cx43 gap junctions
showed significantly increased tumor burden and an attenua-
tion of the inhibitory effect of bisphosphonates on tumor
growth.(111) This study suggests a role of osteocytes and Cx43
hemichannels in the response to bisphosphonates and identifies
Cx43 as a novel therapeutic target.
Denosumab is a fully human monoclonal antibody against
RANKL developed as a novel therapeutic agent to inhibit bone
resorption.(112,113) Denosumab is approved to prevent skeletal-
related events in cancer patients with solid tumors (breast and
prostate) and bone metastases. In a recent study, Roodman and
colleagues found that denosumab has non-inferiority for the
prevention of skeletal-related events in multiple myeloma
patients when compared with zoledronic acid, the mainstay
therapy for this patient population. This study also provided
clinical evidence of a potential anti-myeloma effect based on
RANKL inhibition.(114) Based on these promising results, it is
expected that denosumab becomes an additional option for
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treatment of myeloma patients with bone disease. Given that
osteocytic RANKL is critical in adult bones and cancer cells
increase its expression in osteocytes, it is likely that the potent
antiresorptive effects of denosumab on bone are, at least in part,
due to the inhibition of osteocyte-derived RANKL.
Proteasome inhibitors
Proteasome inhibitors (PIs) prevent the degradation of proteins
targeted with poly-ubiquitin chains.(115) Treatment with PIs
leads to cell cycle arrest and apoptosis in myeloma cancer cells
(reviewed in Obeng and colleagues(116)), decreases osteoclast
formation and resorption capacity,(117) and transiently increases
bone formation.(117) In addition to these effects, new actions of
PIs have been identified in osteocytes. PI therapy decreased the
elevated osteocyte apoptosis found in multiple myeloma
patients with bone lesions and prevented the decrease in
osteocyte viability induced by co-culture with myeloma cells
in vitro.(92) Further, myeloma patients receiving the PI
bortezomib exhibited a 50% decrease in serum Sclerostin.(96)
Neutralizing antibodies against Sclerostin
Several neutralizing antibodies against Sclerostin have been
developed and have shown remarkable ability to stimulate new
bone formation in osteoporotic patients.(118–121) Anti-Sclerostin
antibodies stimulate bone gain by enhancing osteoblast
function while inhibiting bone resorption. Novel, exciting
preclinical data have demonstrated that treatment with anti-
Sclerostin antibodies prevents cancer-induced bone loss and
induces new bone formation in mouse models of multiple
myeloma.(97,100,101) Similarly, anti-Sclerostin therapy also pre-
vented the bone disease induced by breast cancer cells.(95)
Importantly, anti-Sclerostin did not affect tumor burden in any
of these studies. These promising results provide the rationale
for the use of neutralizing antibodies against Sclerostin to
stimulate new bone formation and improve bone mass and
quality in patients with cancer in bone. Yet, further studies are
required to identify the exact source of Sclerostin (osteocytes
versus cancer cells) and to determine the effects of anti-
Sclerostin therapy in other bone metastatic cancers. Because of
the detection of adverse cardiovascular events in patients
treated with anti-Sclerostin,(122,123) the FDA has not yet
approved the use of anti-Sclerostin for the treatment of
osteoporosis. Of note, a new bispecific antibody targeting
both Sclerostin and DKK-1 has been developed.(124) However,
the performance of this bispecific antibody in humans or cancer
is currently unknown.
Pharmacologic inhibition of Notch signaling
Notch signaling between cancer cells and cells present in the
bone/bone marrow microenvironment favors growth and
survival of cancer cells and increases bone resorption (reviewed
in Colombo and colleagues(82,125)). As mentioned before,
physical interactions with myeloma cells activate Notch and
induce a rapid programmed cell death (apoptosis) in osteo-
cytes.(79) In addition, osteocytes reciprocally activate Notch
signaling in myeloma cells to stimulate their proliferation.(79)
Thus, targeting the Notch signaling in themetastatic niche could
result in multiple beneficial outcomes, including decreasing
tumor growth, maintaining osteocyte viability, and inhibiting
bone destruction. However, systemic inhibition of Notch
signaling using GSIs results in severe gut toxicity, limiting their
use in the clinic.(82,125) Targeting specific components of the
Notch pathway has become an attractive approach to avoid the
off-target effects of GSIs. Neutralizing antibodies have been
generated to block the Notch ligands Delta-1 and Jagged-
1(82,125) and are currently being studied in preclinical models.
Another alternative approach to circumvent the side effects of
GSIs is to target Notch inhibitors specifically to the bone.
Inhibition of Notch signaling using a novel bone-targeted GSI
increased bone mass and decreased bone resorption, without
inducing gut toxicity.(126) However, the effects of this novel
agent on tumor growth and cancer-induced bone disease
remain to be determined. Future research efforts are needed to
define the specific effects of Notch signaling in osteocytes and
to determine the effectiveness of targeting the Notch pathway
to treat cancer in bone.
Conclusion and Future Directions
Recent studies have identified osteocytes as important compo-
nents of the cancer microenvironment in bone. We now have
evidence that cancer cells alter osteocyte viability and their
gene expression profile. These changes transform osteocytes
into pro-tumorigenic cells and enhance their osteoclastogenic
potential, leading to tumor growth and bone destruction. In
addition, through the overproduction of Wnt antagonists,
osteocytes also contribute to the suppression of bone forma-
tion. However,muchwork remains to be done to understand the
full involvement of osteocytes in cancer metastases to bone. For
instance, the role of osteocytes in the early steps of bone
metastasis is practically unknown. Moreover, the mechanisms
underlying osteocyte-tumor cell interactions and the conse-
quences for bone homeostasis are not fully understood. Further,
most of the available data derive from myeloma and breast
cancer patients and mouse models. Thus, whether osteocytes
play a similar role in other metastatic cancers remains to be
determined.
Although we have just begun to scratch the surface regarding
the role of osteocytes in cancer, targeting osteocytic pathways
and molecular messengers has already proven to be successful
to prevent/improve the associated bone disease. These
promising results support that targeting osteocytes in the
cancer niche has the potential to guide the development of new
therapeutic regimens for the treatment of cancer in bone. In
conclusion, osteocytes contribute to the progression of cancer
in bone. Thus, full understanding of the mechanisms by which
osteocytes influence cancer cells, osteoblasts, and osteoclasts
should increase the repertoire of pharmacological approaches
to combat cancer in bone.
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